JP2003502359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003502359A5 JP2003502359A5 JP2001504358A JP2001504358A JP2003502359A5 JP 2003502359 A5 JP2003502359 A5 JP 2003502359A5 JP 2001504358 A JP2001504358 A JP 2001504358A JP 2001504358 A JP2001504358 A JP 2001504358A JP 2003502359 A5 JP2003502359 A5 JP 2003502359A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- core material
- alkaline
- form according
- omeprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 description 23
- 239000011162 core material Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000654 additive Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229960000381 omeprazole Drugs 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 159000000011 group IA salts Chemical class 0.000 description 4
- 229920003176 water-insoluble polymer Polymers 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical group 0.000 description 1
- MQEUGMWHWPYFDD-UHFFFAOYSA-N magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical group [Mg].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9902386-3 | 1999-06-22 | ||
| SE9902386A SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | New formulation |
| PCT/SE2000/001310 WO2000078293A1 (en) | 1999-06-22 | 2000-06-20 | New formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003502359A JP2003502359A (ja) | 2003-01-21 |
| JP2003502359A5 true JP2003502359A5 (enExample) | 2007-08-09 |
Family
ID=20416209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001504358A Pending JP2003502359A (ja) | 1999-06-22 | 2000-06-20 | 新規製剤 |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1191926B1 (enExample) |
| JP (1) | JP2003502359A (enExample) |
| KR (1) | KR100717661B1 (enExample) |
| CN (1) | CN1243547C (enExample) |
| AT (1) | ATE291901T1 (enExample) |
| AU (1) | AU778158B2 (enExample) |
| BR (1) | BR0011894A (enExample) |
| CA (1) | CA2376226C (enExample) |
| CZ (1) | CZ20014579A3 (enExample) |
| DE (1) | DE60019116T2 (enExample) |
| DK (1) | DK1191926T3 (enExample) |
| EE (1) | EE200100693A (enExample) |
| ES (1) | ES2235912T3 (enExample) |
| HK (1) | HK1044480B (enExample) |
| HU (1) | HUP0201489A3 (enExample) |
| IL (2) | IL146818A0 (enExample) |
| IS (1) | IS6209A (enExample) |
| MX (1) | MXPA01012636A (enExample) |
| NO (1) | NO20016346L (enExample) |
| NZ (1) | NZ516186A (enExample) |
| PL (1) | PL352873A1 (enExample) |
| PT (1) | PT1191926E (enExample) |
| RU (1) | RU2240110C2 (enExample) |
| SE (1) | SE9902386D0 (enExample) |
| SK (1) | SK285326B6 (enExample) |
| TR (1) | TR200103693T2 (enExample) |
| UA (1) | UA73302C2 (enExample) |
| WO (1) | WO2000078293A1 (enExample) |
| ZA (1) | ZA200109803B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| IL164222A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| SI21402A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| AU2004216405A1 (en) * | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Stable pharmaceutical composition of rabeprazole and processes for their preparation |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1696889A1 (en) * | 2003-08-28 | 2006-09-06 | Ranbaxy Laboratories, Ltd. | Pharmaceutical compositions of benzimidazole and processes for their preparation |
| WO2005020954A2 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
| US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| JP2008510804A (ja) * | 2004-08-23 | 2008-04-10 | オークランド ユニサービシズ リミテッド | 胃の治療法およびそのための組成物 |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| FR2885526B1 (fr) * | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
| US20090175959A1 (en) * | 2005-12-28 | 2009-07-09 | Takeda Pharmaceutical Company Limited | Controlled Release Solid Preparation |
| US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
| DK2046334T3 (da) | 2006-07-25 | 2014-08-25 | Vecta Ltd | Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI |
| WO2008044236A2 (en) * | 2006-10-10 | 2008-04-17 | Dexcel Pharma Technologies Ltd. | Improved release of statins in the intestine |
| CN102209529A (zh) | 2008-09-09 | 2011-10-05 | 阿斯利康(瑞典)有限公司 | 将药物组合物递送至有需要的患者的方法 |
| JP2012531409A (ja) | 2009-06-25 | 2012-12-10 | アストラゼネカ・アクチエボラーグ | Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法 |
| JP6121990B2 (ja) | 2011-05-13 | 2017-04-26 | イービー アイピー ハイブリタブス ビー．ブイ． | 薬物送達システム |
| EP2586429A1 (en) * | 2011-10-26 | 2013-05-01 | Freund Pharmatec Ltd. | Multi-unit drug delivery device for pulsatile or sustained release |
| EA028049B1 (ru) | 2011-12-28 | 2017-10-31 | Поузен Инк. | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты |
| WO2013122554A1 (en) | 2012-02-14 | 2013-08-22 | Mahmut Bilgic | Pellet formulations comprising esomeprazole |
| CN103127026B (zh) * | 2013-02-05 | 2017-02-15 | 悦康药业集团有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
| CA2933166C (en) | 2013-12-31 | 2020-10-27 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| RU2614730C1 (ru) * | 2016-02-05 | 2017-03-28 | Игорь Юрьевич Чичерин | Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза |
| US10736855B2 (en) * | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| JP6426115B2 (ja) * | 2016-04-06 | 2018-11-21 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
| JP6462625B2 (ja) * | 2016-04-06 | 2019-01-30 | ニプロ株式会社 | カルシウムブロッカーを含有する錠剤 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN109125282B (zh) * | 2018-09-05 | 2020-07-14 | 珠海润都制药股份有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| ATE271379T1 (de) * | 1996-11-06 | 2004-08-15 | Wockhardt Europ Ltd | System zur verzögerten freisetzung säurelabiler substanzen |
| SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| HUP0100065A2 (hu) * | 1997-12-08 | 2001-08-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma |
| JP4988088B2 (ja) * | 1998-08-12 | 2012-08-01 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾール、もしくはピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物 |
-
1999
- 1999-06-22 SE SE9902386A patent/SE9902386D0/xx unknown
-
2000
- 2000-06-20 PT PT00946614T patent/PT1191926E/pt unknown
- 2000-06-20 HU HU0201489A patent/HUP0201489A3/hu unknown
- 2000-06-20 DK DK00946614T patent/DK1191926T3/da active
- 2000-06-20 NZ NZ516186A patent/NZ516186A/en unknown
- 2000-06-20 IL IL14681800A patent/IL146818A0/xx active IP Right Grant
- 2000-06-20 EP EP00946614A patent/EP1191926B1/en not_active Expired - Lifetime
- 2000-06-20 AU AU60344/00A patent/AU778158B2/en not_active Ceased
- 2000-06-20 BR BR0011894-0A patent/BR0011894A/pt not_active Application Discontinuation
- 2000-06-20 RU RU2001132861/15A patent/RU2240110C2/ru not_active IP Right Cessation
- 2000-06-20 CN CNB008093369A patent/CN1243547C/zh not_active Expired - Fee Related
- 2000-06-20 SK SK1825-2001A patent/SK285326B6/sk not_active IP Right Cessation
- 2000-06-20 HK HK02106171.6A patent/HK1044480B/en not_active IP Right Cessation
- 2000-06-20 TR TR2001/03693T patent/TR200103693T2/xx unknown
- 2000-06-20 WO PCT/SE2000/001310 patent/WO2000078293A1/en not_active Ceased
- 2000-06-20 UA UA2001128420A patent/UA73302C2/uk unknown
- 2000-06-20 CA CA002376226A patent/CA2376226C/en not_active Expired - Fee Related
- 2000-06-20 KR KR1020017016442A patent/KR100717661B1/ko not_active Expired - Fee Related
- 2000-06-20 MX MXPA01012636A patent/MXPA01012636A/es active IP Right Grant
- 2000-06-20 DE DE60019116T patent/DE60019116T2/de not_active Expired - Lifetime
- 2000-06-20 EE EEP200100693A patent/EE200100693A/xx unknown
- 2000-06-20 ES ES00946614T patent/ES2235912T3/es not_active Expired - Lifetime
- 2000-06-20 CZ CZ20014579A patent/CZ20014579A3/cs unknown
- 2000-06-20 AT AT00946614T patent/ATE291901T1/de not_active IP Right Cessation
- 2000-06-20 PL PL00352873A patent/PL352873A1/xx unknown
- 2000-06-20 JP JP2001504358A patent/JP2003502359A/ja active Pending
-
2001
- 2001-11-28 ZA ZA200109803A patent/ZA200109803B/en unknown
- 2001-11-29 IL IL146818A patent/IL146818A/en not_active IP Right Cessation
- 2001-12-21 IS IS6209A patent/IS6209A/is unknown
- 2001-12-21 NO NO20016346A patent/NO20016346L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502359A5 (enExample) | ||
| CA2407072C (en) | Taste masking coating composition | |
| RU2001132861A (ru) | Новый препарат | |
| US6663893B2 (en) | Taste masking coating composition | |
| JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
| US6034085A (en) | Salt form of nefazodone for use in extended release formulations | |
| AU2001255509A1 (en) | Taste masking coating composition | |
| KR101447909B1 (ko) | 위산 분비의 억제를 위한 조성물 및 방법 | |
| JP2009292843A (ja) | 固形製剤 | |
| JPS6241646B2 (enExample) | ||
| JP4939680B2 (ja) | 固形製剤 | |
| KR20190059868A (ko) | 바레니클린 살리실레이트를 함유하는 서방성 제제 및 이의 제조 방법 | |
| US9370481B2 (en) | Compositions and methods for inhibiting gastric acid secretion | |
| JP2010241760A (ja) | 不快な味の軽減された口腔内速崩壊錠及びその製造方法 | |
| KR20140076998A (ko) | 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법 | |
| WO2010087358A1 (ja) | 新規組成物 | |
| WO2003075919A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie seche) | |
| JP2006528160A (ja) | 抗血栓性化合物の口腔分散性医薬組成物 | |
| JP2008081448A (ja) | 酒石酸ゾルピデムの苦味マスキング速放性粒子 | |
| JP3935539B2 (ja) | フマル酸ケトチフェン含有医薬組成物 | |
| MX2014008975A (es) | Composicion de nitazoxanida mejorada y proceso para prepararla. | |
| JP7404828B2 (ja) | 経口医薬製剤およびその製造方法 | |
| JP2020105173A (ja) | ２種以上の薬物を含有する口腔内崩壊錠及びその製造方法 |